RHRuirong He

Ruirong He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ruirong He has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Bao-Cheng Xie

    Department of Pharmacy, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China

    2 shared publications
  • Han-Bin Zhang

    Department of Pharmacy, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China

    2 shared publications
  • Qiu-Hong Yang

    School of Pharmacy Zunyi Medical University Zunyi China

    2 shared publications
  • Wei-Chao Han

    Department of Pharmacy, The Tenth Affiliated Hospital of Southern Medical University (Dongguan People’s Hospital), Dongguan, China

    2 shared publications
  • Weichao Han

    Department of Pharmacy, Affiliated Dongguan Hospital, Southern Medical University

    2 shared publications
  • Ying-Ying Shao

    Department of Pharmacy The Tenth Affiliated Hospital of Southern Medical University (Dongguan People's Hospital) Dongguan China

    2 shared publications

Latest Publications

  • Open Access

    Molecular targets and mechanisms of cortex mori for lung cancer treatment: a network pharmacology study, molecular docking and in vitro and in vivo experimental validation

    by Ying-Ying Shao, Qiu-Hong Yang, Shu-Fen He, Han-Bin Zhang, Wei-Chao Han, Bao-Cheng Xie, Rui-Rong He, Wen-Xin Hong

    Introduction: The cortex mori comes from the white endothelium of the young root of Morus alba L., and its medical value was first described in Shen Nong Ben Cao Jing (Classic on Materia Medical of Shennong). It was originally intended to purge lung, relieve asthma and reduce swelling. More and more studies reported that its pharmacological effects include analgesic, anti-inflammatory, antitussive, antiasthmatic, hypoglycemic, hypolipidemic and anti-diabetic peripheral neuropathy. Accumulating clinical evidences exhibited that it can treat asthma, pneumonia and lung cancer. However, a comprehensive mechanism of cortex mori in the treatment of lung cancer needs to be further elucidated.To investigate the effect of cortex mori and its active components against lung cancer and explore its action and mechanism through network pharmacological analysis combined with biological experiments in vitro and In vivo.Methods: GeneCards database was searched for the disease targets of lung cancer, and a Chinese medicine database, Traditional Chinese Medicine Systems Pharmacology (TCMSP), was used to screen cortex mori for its active components and targets. Targets related to lung cancer and action targets related to cortex mori were crossed. Protein-protein interactions (PPI) and gene ontologies (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were analyzed for intersection genes. In order to determine whether cortex mori affects lung cancer, MTS, wound healing, Western-blot, Hoechst assay, apoptosis assay and animal experiments were performed.Results: 32 active ingredients and 434 targets of Chinese medicine cortex mori were obtained. Totally 2,3107 lung cancer related targets were collected, and 163 Chinese medicine-disease targets were derived from the intersection. The regulatory network of Chinese medicine-active ingredient-disease-targets showed that cortex mori acted on 163 disease targets of lung cancer mainly by cyclomolorusin, kuwanon D and Moracin A, etc. The core genes involving cortex mori treating lung cancer might consist of JUN, AKT1, etc. The core targets involved 162 biological processes, mainly including nuclear receptor activity, ligand-actived transcription factor activity, etc. The core study targeted 160 pathways, including AGE-RAGE signaling pathways associated with diabetes complications, fluid stress and atherosclerosis. Biologic cytological experiments showed that the effective active component cyclomorusin inhibited proliferation, inhibited migration and induced apoptosis of lung cancer through AKT-PI3K pathway. In vivo antitumor assay demonstrated that cyclomolorusin suppressed the tumor growth in mice.Discussion: Cortex mori acts on AKT and other related disease targets of lung cancer cells through effective components such as cyclomolorusin, and plays a role in the treatment of lung cancer by inhibiting the signaling pathway associated with lung cancer occurrence and development.

  • Open Access

    Molecular targets and mechanisms of cortex mori for lung cancer treatment: A network pharmacology study, molecular docking and experimental validation

    by Qiuhong Yang, Yingying Shao, Shufen He, Hanbin Zhang, Weichao Han, Baocheng Xie, Ruirong He

    Purpose The traditional Chinese medicine cortex mori was commonly used to treat pneumonia in clinical settings. The development of cancer is closely related to inflammation. So, it was the objective of this study to determine the molecular targets of cortex mori in the treatment of lung cancer and explore its action and mechanism through network pharmacological analysis combined with biological experiments in vitro. Methods GeneCards database was searched for the disease targets of lung cancer and Traditional Chinese Medicine Systems Pharmacology (TCMSP), was used to screen cortex mori for its active components and targets. Protein-protein interactions (PPI) and gene ontologies (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were analyzed for intersection genes. In order to determine whether cortex mori affects lung cancer, MTS, wound healing, and apoptosis assays were performed. Results 32 active ingredients and 434 targets of Chinese medicine cortex mori were obtained. Totally 2,3107 lung cancer related targets were collected. The results of network pharmacological analysis showed that cortex mori acted on 163 disease targets of lung cancer mainly by cyclomolorusin, ,etc. The core genes involving cortex mori treating lung cancer might consist of JUN, etc. The core targets involved 162 biological processes, including nuclear receptor activity, etc. The core study targeted 160 pathways, including fluid stress, etc. Biologic cytological experiments showed that cyclomolorusin inhibited occurrence and development of lung cancer through AKT-PI3K pathway. Conclusions Cortex mori acts on AKT and other related disease targets of lung cancer cells through cyclomolorusin, and plays a role in the treatment of lung cancer by inhibiting the signaling pathway associated with lung cancer occurrence and development.

  • Open Access

    A pan-cancer study of the role of lysine specific demethylase 1 (LSD1) in human cancers

    by Ying-Ying Shao, Qiu-Hong Yang, Han-Bin Zhang, Bao-Cheng Xie, Wei-Chao Han, Yong-Xiang Xu, Shao-Bo Ding, Rui-Rong He

    Objectives: To conduct a pan-cancer analysis of a relationship between LSD1 and cancer. Setting: Although increasing evidence from cell- or animal-based research supports the existence of a relationship between LSD1 and cancer, there is no pan-cancer analysis. Data sources: Databases, including TCGA, and GEO. Results: On the basis of the TCGA and GEO datasets, we first found that LSD1 may contribute to tumorigenesis across 34 tumor types. LSD1 is expressed in most cancers at a higher level than in normal tissues, and there are distinguishable differences between the LSD1 expression and prognosis of patients. We found that the phosphorylation level of S166 is highly expressed in several tumors, including breast cancer, uterine corpus endometrial carcinoma and lung adenocarcinoma. There was an association between the expression of LSD1 and the infiltration of cancer-associated fibroblasts in BRCA, CESC, ESCA, HNSC, KIRC, LUAD, LUSC, PAAD and PCPG. In addition, RNA transport, mRNA surveillance pathways, and spliceosome -associated functions are also involved in the molecular mechanisms of LSD1. Conclusions: This pan-cancer study provides a fairly comprehensive description of the oncogenic roles of LSD1 in a wide variety of tumors.

  • Open Access

    Epimedin C Alleviates Glucocorticoid-Induced Suppression of Osteogenic Differentiation by Modulating PI3K/AKT/RUNX2 Signaling Pathway

    by Yongxiang Xu, Shichun Chen, Linxuan Huang, Weichao Han, Yingying Shao, Minyi Chen, Yusheng Zhang, Ruirong He, Baocheng Xie

    Secondary osteoporosis is triggered mostly by glucocorticoid (GC) therapy. Dexamethasone (DEX) was reported to inhibit osteogenic differentiation in zebrafish larvae and MC3T3-E1 cells in prior research. In this research, we primarily examined the protective impacts of epimedin C on the osteogenic inhibition impact of MC3T3-E1 cells and zebrafish larvae mediated by DEX. The findings illustrated no apparent toxicity for MC3T3-E1 cells after administering epimedin C at increasing dosages from 1 to 60 μM and no remarkable proliferation in MC3T3-E1 cells treated using DEX. In MC3T3-E1 cells that had been treated using DEX, we discovered that epimedin C enhanced alkaline phosphatase activities and mineralization. Epimedin C could substantially enhance the protein expression of osterix (OSX), Runt-related transcription factor 2 (RUNX2), and alkaline phosphatase (ALPL) in MC3T3-E1 cells subjected to DEX treatment. Additionally, epimedin C stimulated PI3K and AKT signaling pathways in MC3T3-E1 cells that had been treated using DEX. Furthermore, in a zebrafish larvae model, epimedin C was shown to enhance bone mineralization in DEX-mediated bone impairment. We also found that epimedin C enhanced ALPL activity and mineralization in MC3T3-E1 cells treated using DEX, which may be reversed by PI3K inhibitor (LY294002). LY294002 can also reverse the protective impact of epimedin C on DEX-mediated bone impairment in zebrafish larval. These findings suggested that epimedin C alleviated the suppressive impact of DEX on the osteogenesis of zebrafish larval and MC3T3-E1 cells via triggering the PI3K and AKT signaling pathways. Epimedin C has significant potential in the development of innovative drugs for the treatment of glucocorticoid-mediated osteoporosis.


  • Open Access

    Clinical Efficacy and Safety of Human Mesenchymal Stem Cell Therapy for Degenerative Disc Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Baocheng Xie, Shichun Chen, Yongxiang Xu, Weichao Han, Runkai Hu, Minyi Chen, Ruirong He, Shaobo Ding

    Degenerative disc disease (DDD) can cause severe low back pain, which will have a serious negative impact on the ability to perform daily tasks or activities. For the past few years, mesenchymal stem cell (MSC) transplantation has emerged as a promising strategy for the treatment of DDD. However, the clinical efficacy of MSC in the treatment of DDD still lacks clinical evidence and is controversial. We conducted a meta-analysis with randomized controlled trials (RCTs) to evaluate the clinical efficacy and safety of MSC transplantation in patients with DDD. We searched major databases using terms from the database’s inception through March 2021. The Cochrane bias risk assessment tool was used to assess quality. The analysis showed that MSC therapy could decrease visual analog scale (VAS) scores ( , , ) and Oswestry Disability Index (ODI) scores ( , , ). The outcomes with subgroup analysis showed that MSC therapy could decrease VAS scores in 3 months ( ), 6 months ( ), 12 months ( ), and ≥24 months ( ) and ODI scores in ≥24 months ( ). Pooled analysis showed that MSC therapy has a higher ratio of patients at most thresholds but particularly at the MIC (minimally important change) (<use...